Expansion of Particle Therapy at Heidelberg University Hospital
Heidelberg University Hospital (Universitätsklinikum Heidelberg AöR, UKHD) is proud to announce a significant enhancement to its particle therapy program through a new partnership with IBA (Ion Beam Applications S.A., EURONEXT). This initiative focuses on the installation of the innovative ProteusONE compact proton therapy system, designed to deliver specialized cancer treatments to patients. The first payment for this cutting-edge system has already been processed, marking an important milestone in this partnership.
The Significance of the ProteusONE System
The introduction of the ProteusONE system reflects a strategic enhancement of UKHD’s particle therapy program, which has been a leader in the field since 2010. This system utilizes the latest advancements in proton therapy, providing patients with highly targeted cancer treatment options. The investment reinforces UKHD's position as a premier global reference center in precision radiation oncology, blending scientific advances with a focus on patient-centered care.
Operational Details and Future Expectations
The contract signed between IBA and UKHD follows rigorous procedures aimed at compliance with EU and German procurement regulations. Included in this contract are provisions for the ongoing operation and maintenance of the ProteusONE system over multiple years. UKHD anticipates launching treatment services for its first patients around the latter half of 2030.
Insights from Leadership
Olivier Legrain, the Chief Executive Officer of IBA, expressed enthusiasm about the collaboration, stating, "Collaborating with such a renowned institution demonstrates our commitment to excellence in particle therapy. We look forward to working closely with the esteemed team at Heidelberg University Hospital to deliver exceptional patient benefits across Germany." This sentiment of innovation was echoed by Prof. Dr. med. Dr. rer. nat. Jürgen Debus, the Chief Medical Director at UKHD, who remarked on the promise of integrating IBA’s advanced technology into their existing treatment programs. He noted that the ProteusONE system's streamlined workflow will enhance their capacity for treating cancer patients with proton therapy.
The Financial Aspects of the Investment
The financial commitment associated with acquiring a ProteusONE system, along with a multi-year maintenance agreement, typically ranges from EUR 35 to 45 million. This investment underscores UKHD's dedication to providing top-tier healthcare services through modern and effective treatment methods.
About IBA
Based in Louvain-la-Neuve, Belgium, IBA is recognized as a leading innovator in particle accelerator technology. As the leading provider of proton therapy solutions globally, IBA is committed to advanced cancer treatments, industrial sterilization, and medical dosimetry. With a workforce of approximately 2,100 employees, IBA is also a certified B Corporation, emphasizing its commitment to social and environmental responsibility. It is publicly listed on the EURONEXT exchange under the ticker IBAB.
About Heidelberg University Hospital
Universitätsklinikum Heidelberg, established over 600 years ago, stands as a leading medical center in Europe, prioritizing high-quality patient care alongside cutting-edge research and educational initiatives. It has been a pioneer in the realm of particle therapy, exemplified by the establishment of the Heidelberg Ion-Beam Therapy Center (HIT), which was the first hospital-based facility in Europe to offer both proton and heavy ion therapies.
Frequently Asked Questions
What is the ProteusONE system?
The ProteusONE system is an advanced compact proton therapy solution designed to deliver highly targeted cancer treatments using state-of-the-art technology.
When will the first patients be treated with the new system?
Heidelberg University Hospital plans to commence treatment for its first patients in the latter half of 2030.
What is the investment range for the ProteusONE system?
The typical investment for a ProteusONE system, including a multi-year maintenance agreement, ranges between EUR 35 million and EUR 45 million.
Who is IBA?
IBA is Ion Beam Applications S.A., a leading provider of proton therapy solutions and particle accelerator technology, committed to enhancing cancer care worldwide.
Why is particle therapy important?
Particle therapy, including proton therapy, is crucial for delivering precise cancer treatments that minimize damage to surrounding healthy tissues, increasing the effectiveness of treatment.
